Drug Trial Radar · NCT06732895
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
25
Actual
Start
Dec 10, 2024
Primary completion
Sep 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Ascendis Pharma A/SIndustry
- Sponsor type
- Industry
- First posted
- Dec 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of navepegritide 100 μg/kg compared to placebo (inactive drug) in adolescents aged 12 to 18 years with Achondroplasia. What will be measured is Annualized Growth Velocity after a 52-week treatment period.
Conditions
- Achondroplasia
Interventions
NavepegritideDrug
Once-weekly subcutaneous injection of 100 µg/kg navepegritide for 52 weeks
Placebo for navepegritideDrug
Once-weekly subcutaneous injection of 100 µg/kg placebo for navepegritide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Growth VelocityTime frame: 52 weeks
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
Ascendis Investigational Site
Montreal, Canada
Ascendis Investigational Site
Copenhagen, Denmark
Ascendis Investigational Site
Paris, France
Ascendis Investigational Site
Dublin, Ireland
Ascendis Investigational Site
Norwich, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.